Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
Context: Medical therapy for Cushing syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this goal. Objective: We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS. Methods: A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60 to 90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using ultra-high performance liquid chromatography–tandem mass spectrometry. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes. Results: Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2 ± 1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon to early morning period (AUC16:00-08:00: −6.1 [−0.15 to −12.1] ng/mL/h, P = .029). Quality of life and sleep improved (CushingQoL: +4.2, P = .029; Pittsburgh Sleep Quality Index: −1.7, P = .049). Serum steroid precursors, including 11-deoxycorticosterone (−3.1 ng/mL/h, P = .008) and 11-deoxycortisol (−17.8 ng/mL/h, P = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, electrocardiogram abnormalities, or loss of disease control. Conclusion: Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, evidence suggests that restoring cortisol circadian rhythm may improve disease control and alleviate symptoms (39-43).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Although this can be achieved after successful surgery selectively removing the source of excess ACTH or cortisol, normalization of the cortisol circadian rhythm after most medical therapies has rarely been investigated and is not routinely measured to assess treatment response (39-44).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Once-daily osilodrostat dosing significantly reduced late afternoon to early morning cortisol exposure while maintaining morning peak concentrations, thereby improving cortisol circadian rhythms even in patients with well-controlled CS.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, patient-reported outcomes of quality of life and sleep showed significant improvement.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationDiagnosis and Management of Pituitary Adenomas: A Review
Tritos, N. A., & Miller, K. K. (2023) · JAMA · doi:10.1001/jama.2023.5444 · Cited by 331
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Webb, S. M., Badia, X., Barahona, M. J., Colao, A., Strasburger, C. J., Tabarin, A., van Aken, M. O., Pivonello, R., Stalla, G., Lamberts, S. W. J., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0762 · Cited by 229
Self-citation
Cited by
Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome
Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 24
Effects of metyrapone in patients with mild hypercortisolism
Musolino, A., Favero, V., Parazzoli, C., Aresta, C., Testa, S., Persani, L., Corbetta, S., Chiodini, I., & Morelli, V. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf216 · Cited by 7
Paragliola, R. M., Marchetti, M., Montagna, C., Corsello, S. M., & Peluso, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211230 · Cited by 9
Piazzola, C., Castinetti, F., von Fabeck, K., & Simon, N. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf185 · Cited by 5
Działach, Ł., Respondek, W., Siejka, A., & Witek, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1629387 · Cited by 5
Metadata
- Authors
- Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., Minnetti, M., Sbardella, E., Venneri, M. A., Pofi, R., Pivonello, R., Gianfrilli, D., Hasenmajer, V., & Isidori, A. M.
- Affiliations
- Sapienza University of Rome (IT)
- University of Naples Federico II (IT)
- Department of Experimental Medicine, “Sapienza” University of Rome , Rome 00161 ,
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II di Napoli , Naples 80131 ,
- Churchill Hospital (GB)
- Policlinico Umberto I (IT)
- Corresponding author
- Isidori, Andrea M
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2025-04-02
- Volume
- 110
- Issue
- 12
- Pages
- 3525-3537
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC12623021
- OpenAlex
- W4409093251
- Semantic Scholar
- 3e0fef2e8fad28a14b1f8da8d3696b2e32d90a75
- Cited by
- 28
- References
- 71
- Citations by year
- 2026: 15 · 2025: 13
- FWCI
- 19.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- European Union—NextGenerationEU
- Italian Ministry of University and Research (PNRR - M4C2-I1.3)
- CUP (B53C22004000006)
- Ministerial Research Project (PRIN PNRR Prot. P2022EA9RR_001)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, osilodrostat, chronotherapy, once-daily dosing, diurnal cortisol rhythm, salivary cortisol, quality of life, sleep quality, deoxycorticosterone, 11-deoxycortisol, adrenal insufficiency, pituitary Cushing's disease, timing of drug administration
- MeSH terms
- Adult, Aged, Circadian Rhythm, Cushing Syndrome, Female, Humans, Hydrocortisone, Imidazoles, Male, Middle Aged, Prospective Studies, Pyridines, Quality of Life, Saliva, Sleep, Treatment Outcome, Chronotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. https://app.cochat.ai/papers/10.1210/clinem/dgaf206
- The paper
- Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., Minnetti, M., Sbardella, E., Venneri, M. A., Pofi, R., Pivonello, R., Gianfrilli, D., Hasenmajer, V., & Isidori, A. M. (2025). Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf206
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.